Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC2 | Q92887 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18167424 | 1.00 | ABCC2 (0.40) | ABCC2OPRK1MAPTTDP1 | |
| SCHEMBL17965893 | 1.00 | ABCC2 (0.40) | ABCC2OPRK1MAPTTDP1 | |
| SCHEMBL18167420 | 1.00 | ABCC2 (0.40) | ABCC2OPRK1MAPTTDP1 | |
| SCHEMBL18167421 | 1.00 | ABCC2 (0.40) | ABCC2OPRK1MAPTTDP1 | |
| SCHEMBL16608964 | 0.88 | RET (0.41) | ABCC2OPRK1MAPTTDP1 | |
| SCHEMBL16608958 | 0.88 | RET (0.41) | ABCC2OPRK1MAPTTDP1 | |
| SCHEMBL16608911 | 0.88 | RET (0.41) | ABCC2OPRK1MAPTTDP1 | |
| SCHEMBL16608907 | 0.88 | RET (0.41) | ABCC2OPRK1MAPTTDP1 | |
| SCHEMBL17965887 | 0.80 | POLB (0.38) | OPRK1MAPTTDP1 | |
| SCHEMBL15873376 | 0.79 | ALDH1A1 (0.42) | OPRK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9643951-B2 | Compound having somatostatin receptor agonistic activity and pharmaceutical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-05-09 | — | — | US | disclosed |
| US-20160311794-A1 | COMPOUND HAVING SOMATOSTATIN RECEPTOR AGONISTIC ACTIVITY AND PHARMACEUTICAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311794-A1 | COMPOUND HAVING SOMATOSTATIN RECEPTOR AGONISTIC ACTIVITY AND PHARMACEUTICAL USE THEREOF | SSTR1, SSTR2, SSTR3 | ABCC2 2970/4885OPRK1 1050/4885MAPT 3905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.